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Piperazine derived drugs emerged on the drug market in the last decade. The aim of this study was to
investigate in vitro the potential hepatotoxicity of the designer drugs N-benzylpiperazine (BZP), 1-(3-tri-
ﬂuoromethylphenyl)piperazine (TFMPP), 1-(4-methoxyphenyl)piperazine (MeOPP) and 1-(3,4-
methylenedioxybenzyl)piperazine (MDBP) in two human hepatic cell lines (HepaRG and HepG2) and
in primary rat hepatocytes. Cell death was evaluated by the MTT assay, after 24 h-incubations. Among
the tested drugs, TFMPP was the most cytotoxic. HepaRG cells and primary hepatocytes revealed to be
the most and the least resistant cellular models, respectively. To ascertain whether the CYP450 metabo-
lism could explain their higher susceptibility, primary hepatocytes were co-incubated with the piperazi-
nes and the CYP450 inhibitors metyrapone and quinidine, showing that CYP450-mediated metabolism
contributes to the detoxiﬁcation of these drugs. Additionally, the intracellular contents of reactive spe-
cies, ATP, reduced (GSH) and oxidized (GSSG) glutathione, changes in mitochondrial membrane potential
(Dwm) and caspase-3 activation were further evaluated in primary cells. Overall, an increase in reactive
species formation, followed by intracellular GSH and ATP depletion, loss ofDwm and caspase-3 activation
was observed for all piperazines, in a concentration-dependent manner. In conclusion, piperazine
designer drugs produce hepatic detrimental effects that can vary in magnitude among the different
analogues.
 2015 Elsevier Ltd. All rights reserved.1. Introduction
Piperazine derived drugs emerged on the drug market in last
decade and have been often found as one of the main psychoactive
substances present in tablets and pills sold on the internet (Davies
et al., 2010). Initially, these drugs were commercialized as a legal
alternative to 3,4-methylenedioxymethamphetamine (MDMA or
ecstasy) but nowadays they are prohibited in most countries
(Arbo et al., 2012).
Pharmacologically, piperazine designer drugs present a clear
stimulant-like pattern of behavioral effects associated with
increases in monoamines release (Baumann et al., 2005; Meririne
et al., 2006; Yarosh et al., 2007). Users have experienced tachycar-
dia, hypertension, anxiety, vomiting, migraine, palpitations, confu-
sion, collapse, and seizures (Gijsman et al., 1998; Feuchtl et al.,
2004; Gee et al., 2005; Thompson et al., 2010; Lin et al., 2011;
Wood et al., 2008; Kovaleva et al., 2008), acute psychotic episodesand hallucinations (Austin and Monasterio, 2004), severe
nephrotoxicity (Alansari and Hamilton, 2006), hyperthermia,
disseminated intravascular coagulation, rhabdomyolysis and
renal failure (Gee et al., 2010). A lethal intoxication case with
death after massive brain oedema (Balmelli et al., 2001) has also
been reported. Recent preliminary evidence suggest that BZP is
highly toxic to heart and kidney cell lines, which may explain the
symptoms of renal and cardiovascular toxicity in users (Arbo
et al., 2012, 2014; Monteiro et al., 2013). Hepatic liver failure has
also been reported after BZP intake (Cole, 2011; Monteiro et al.,
2013).
Pharmacokinetic data is limited however, there is evidence indi-
cating that piperazine designer drugs aremainlymetabolized in the
liver, where they can also accumulate (Antia et al., 2009), being the
phenylpiperazines, such as 1-(3-triﬂuoromethylphenyl)piperazine
(TFMPP), and 1-(4-methoxyphenyl)piperazine (MeOPP) more
extensively metabolized than the benzylpiperazines, such as
N-benzylpiperazine (BZP) and its methylenedioxy-analogue
1-(3,4-methylenedioxybenzyl)piperazine (MDBP) (Maurer et al.,
2004). They are excreted almost exclusively as metabolites, in
urine, in humans and in animal models (Maurer et al., 2004), but
there is wide variation in the excretion rate among different
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(Austin and Monasterio, 2004).
Hepatocytes are of particular interest as they have a central
function in the metabolic fate and, consequently, in the process
of detoxiﬁcation and toxiﬁcation of xenobiotics. Also, the liver is
known to be one of the main targets for the toxicity of ampheta-
mine like-drugs in humans (Carvalho et al., 2010). Therefore, the
study of the hepatic deleterious effects triggered by piperazine
designer drugs is of particular interest. The aim of the current work
was to evaluate and compare the potential hepatotoxicity of BZP,
TFMPP, MeOPP, and MDBP in different in vitro models including,
the human hepatoma HepG2 and HepaRG cell lines, and rat pri-
mary hepatocytes.2. Material and methods
2.1. Chemicals
N-Benzylpiperazine (BZP, 99.3% purity) was purchased from
Chemos GmbH (Regenstauf, Germany), 1-(3-triﬂuo-
romethylphenyl)piperazine (TFMPP, 98% purity) from Alfa Aesar
(Karlsruhe, Germany), 1-(4-methoxyphenyl)piperazine (MeOPP,
96% purity) from Acros Organics (New Jersey, USA), and 1-(3,
4-methylenedioxybenzyl)piperazine (MDBP, 97% purity) from
Aldrich Chemistry (Steinheim, Germany). Dulbecco’s modiﬁed
eagle’s medium (DMEM) with high glucose, heat-inactivated fetal
bovine serum (FBS), 0.25% trypsin/1 mM EDTA, antibiotic solution
(10,000 U/mL penicillin, 10,000 lg/mL streptomycin), Hanks
balanced salt solution (HBSS), and phosphate buffer (PBS) were
purchased from Invitrogen Corporations (Paisley, UK). Unless
stated otherwise, all other chemicals and reagents were obtained
from Sigma–Aldrich (St. Louis, USA).
Stock solutions of BZP were made up in PBS. Stock solutions of
TFMPP, MeOPP and MDBP were made in dimethyl sulfoxide
(DMSO). In these cases, DMSO did not exceed 1% in culture media
and it was used as solvent control. In all experiments, a comparison
between solvent and negative (cells treated with cell culture
medium) control was performed and no statistically signiﬁcant
differences between negative and solvent controls were observed
(p > 0.05). All stock solutions were stored at 20 C and freshly
diluted on the day of the experiment.2.2. Immortalized cell culture
HepG2 cells were kindly provided by Prof. Ricardo Dinis-
Oliveira (Department of Sciences, Advanced Institute of Health
Sciences—North, CESPU, CRL, Gandra, Portugal). Cells were rou-
tinely cultured in 75 cm2 ﬂasks using DMEM with high glucose
medium, supplemented with 10% FBS and 1% antibiotic solution.
Cells were maintained in a humidiﬁed 5% CO2 – 95% air atmo-
sphere at 37 C, and the medium was changed every 2–3 days.
Cultures were passaged by trypsinization (0.25% trypsin/1 mM
EDTA) when cells reached 70–80% conﬂuence, and were subcul-
tured over a maximum of 10 passages. For the MTT assay, cells
were seeded at a density of 80,000 cells/well onto 96-well plates
(BD Biosciences, Oxford, UK) in a volume of 100 lL of complete cul-
ture medium, to obtain conﬂuent monolayers within 24 h. The fol-
lowing day the cells were incubated with the test drugs in cell
culture medium without FBS. To enable reliable, complete concen-
tration–response curves for each drug, HepG2 cells were exposed
in triplicates to a wide range of concentrations (from 39 lM to
35 mM for BZP; 4.6 lM to 3 mM for TFMPP; 51.4 lM to
16.36 mM for MeOPP; and 68.5 lM to 30 mM for MDBP), in four
independent experiments.HepaRG cells were purchased from Life Technologies
(Invitrogen, France) and cultured in 75 cm2 ﬂasks using Williams’
Medium E with L-glutamine, supplemented with 10% FBS and 1%
antibiotic solution, 50 lM hydrocortisone 21-hemisuccinate
sodium salt and 5 lg/mL insulin. Cells were maintained in a
humidiﬁed 5% CO2 – 95% air atmosphere at 37 C, and the medium
was changed every 2–3 days. Cultures were passaged by
trypsinization (0.25% trypsin/1 mM EDTA) when cells reached
70–80% conﬂuence, and were subcultured over a maximum of 10
passages. For the MTT assay, cells were seeded at a density of
144,000 cells/well onto 96-well plates (BD Biosciences, Oxford,
UK) in a volume of 100 lL of complete culture medium and
allowed to grow. When cells reached conﬂuence, differentiation
was induced by replacing the complete culture medium with dif-
ferentiation medium (Williams’ Medium E with L-glutamine with
no FBS, supplemented with 1% antibiotic solution, 50 lM hydro-
cortisone 21-hemisuccinate sodium salt, 5 lg/mL insulin, and 2%
DMSO). The differentiation medium was replaced every 48 h, dur-
ing 15 days. The following day, HepaRG cells were incubated with
the test drugs in culture medium without FBS to a wide range of
concentrations (from 14 lM to 40 mM for BZP; 1 lM to 3 mM for
TFMPP; 3 lM to 20 mM for MeOPP; and 3 lM to 20 mM for
MDBP), in triplicates, in eight independent experiments.
2.3. Animals
Male Wistar rats with a body weight of 200–250 g were pur-
chased from Charles-River Laboratories (Barcelona, Spain). The ani-
mals had access to food (standard rat chow) and tap water
ad libitum and were kept under controlled temperature
(20 ± 2 C), humidity (40–60%) and lighting (12 h light/dark cycle
conditions). The animals were acclimatized in polyethylene cages,
for 1 week prior to use. Surgical procedures for the isolation of hep-
atocytes were performed under anesthesia with isoﬂurane
(IsoFlo, Abbot Laboratories, Berkshire, UK), and were carried out
always between 10:00 and 11:00 a.m. This study was approved
by the local committee for the welfare of experimental animals
and was performed in accordance with national legislation.
2.4. Isolation and culture of primary rat hepatocytes
Hepatocytes isolation was performed by collagenase perfusion
as previously described (Moldéus et al., 1978) with some modiﬁca-
tions. Brieﬂy, after perfusion with a chelating agent (600 lM EGTA)
to allow the cleavage of the hepatic desmosomes, hepatic collagen
was hydrolyzed by ex situ perfusion with a 100 U/mL collagenase
type 1, from Clostridium histolyticum solution supplemented with
5.3 lM CaCl2. The hepatocytes were dissociated in Krebs–
Henseleit buffer and the obtained suspension was puriﬁed by
low-speed centrifugations and incubated for 30 min, at 4 C, with
1% antibiotic. The initial viability of the isolated hepatocytes sus-
pensions was always above 85%, as estimated by the trypan blue
exclusion test. A suspension of 5  105 viable cells/mL in complete
culture medium (William’s E medium supplemented with 10% FBS,
2 ng/mL insulin, 5 nM dexamethasone, 1% antibiotic solution,
10 lg/mL gentamicin, and 0.25 lg/mL amphotericin B) was seeded
onto 96-well plates (BD Biosciences, Oxford, UK). Cells were incu-
bated at 36.5 C with 5% CO2, overnight for cell adhesion. The fol-
lowing day, the cells were incubated in cell culture medium
without FBS with a wide range of concentrations (from 45 lM to
40 mM for BZP; 0.4 lM to 2.5 mM for TFMPP; 2.22 lM to 20 mM
for MeOPP; and 2.22 lM to 20 mM for MDBP) of the test drugs
for the cytotoxicity experiments. Each concentration was tested
in triplicate in nine independent experiments. Since primary rat
hepatocytes proved to be the most sensitive model to the cytotox-
icity induced by the piperazine designer drugs, all the subsequent
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this cellular model by testing three different concentrations for
each test substance that corresponded to 3 different cytotoxicity
levels, the EC20, EC40 and EC60 of each drug according to the MTT
concentration–response curves. The concentrations tested were:
1.06, 1.66, and 2.78 mM for BZP; 88, 113, and 152 lM for TFMPP;
1.44, 1.82, and 2.37 mM for MeOPP; and 2.40, 3.18, and 4.38 mM
for MDBP.
2.5. Cytotoxicity assays
For the evaluation of cytotoxicity, the MTT reduction assay was
performed. The MTT assay measures succinate dehydrogenase
activity, an indicator of metabolically active mitochondria, and
therefore of cell viability. A protocol previously described by Dias
da Silva et al. (2013a) was used. The absorbance was measured
at 550 nm in a multi-well plate reader (BioTek Instruments,
Vermont, USA). Results were graphically presented as percentage
of cell death relative to control versus concentration (mM). 1%
DMSO was used as solvent control and 1% Triton X-100 as positive
control.
2.6. Inﬂuence of CYP metabolism on piperazine designer drugs
cytotoxicity
To clarify the inﬂuence of CYP450 metabolism on the cytotoxi-
city elicited by the tested piperazines, primary rat hepatocytes
were seeded at 5  105 viable cells/mL density onto 96 well-plates.
After 24 h, the cells were co-incubated with each tested piperazine
designer drug and 500 lM metyrapone (non selective inhibitor of
the cytochrome P450) or 100 lM quinidine hydrochloride mono-
hydrate (CYP2D6 inhibitor) (Turpeinen et al., 2004). The CYP2D6
was speciﬁcally inhibited because it is the main CYP450 isoenzyme
responsible for the piperazine designer drug metabolism in vivo
(Staack and Maurer, 2005). After 24 h, cell mortality was deter-
mined through the MTT assay. The ﬁnal results were expressed
as % of control conditions from 3 independent experiments with
each concentration tested in 3 replicates within each experiment.
2.7. Measurement of intracellular reactive oxygen (ROS) and nitrogen
(RNS) species
The intracellular ROS and RNS production was monitored by
means of the DCFH-DA assay as previously described (Dias da
Silva et al., 2014a). On the day of the experiment, primary rat hep-
atocytes were seeded onto 96-well plates at a density of 5  104 -
viable cells/well and incubated with 10 lMDCFH-DA for 30 min, at
37 C, in the dark. As DCFH-DA is a non-water-soluble powder, it
was initially prepared as a 4 mM stock solution in DMSO and made
up to the ﬁnal concentration in fresh culture medium (ensuring
that the ﬁnal concentration of DMSO did not exceed 0.05%) imme-
diately before each experiment. The cells were then rinsed with
HBSS and incubated with the EC20, EC40 and EC60 of each piperazine
designer drug (based on the MTT concentration–response curves),
at 37 C during 24 h. Fluorescence was recorded on a ﬂuorescence
microplate reader (BioTek Instruments, Vermont, USA) set to
485 nm excitation and 530 nm emission. The data are presented
as the percentage of control conditions from four independent
experiments with each concentration tested in six replicates
within each experiment.
2.8. Measurement of intracellular reduced glutathione (GSH), and
oxidized glutathione (GSSG)
Primary rat hepatocytes were seeded onto 6-well plates at
1  106 viable cells/well density. After 24 h incubations with theEC20, EC40 and EC60 of each drug at 37 C, the cells were rinsed with
HBSS and scrapped/precipitated with 5% perchloric acid (HClO4, w/
v). After centrifugation (16,000g, 10 min, 4 C), the supernatants
were collected and kept at 80 C until further determination of
GSH and GSSG. The pellet obtained was resuspended in 0.3 M
NaOH and used for protein quantiﬁcation, determined by the
Lowry assay (Lowry et al., 1951).
The intracellular levels of GSH and GSSG were evaluated by the
DTNB-GSSG reductase-recycling assay, as previously described
(Dias da Silva et al., 2014a). Data from four independent experi-
ments were normalized to the protein content and the ﬁnal results
were expressed as nmol per mg of protein.
2.9. Measurement of intracellular ATP
Samples were prepared as described for the GSH and GSSG
measurement. The ATP levels were quantiﬁed by a biolumines-
cence assay, as described by Pontes et al. (2008). The emitted light
intensity was determined using a luminescence microplate reader
(BioTek Instruments, Vermont, USA) and compared with a stan-
dard curve performed within each experiment. Data were normal-
ized to the protein content, determined by the Lowry assay (Lowry
et al., 1951), and results from four independent experiments were
expressed as nmol per mg of protein.
2.10. Assessment of mitochondrial membrane potential (Dwm)
Assessment of mitochondrial integrity was performed by mea-
suring TMRE inclusion as described by Dias da Silva et al.
(2014a). Primary rat hepatocytes, seeded at a 5  104 viable cells/
well density onto 96-well plates, were incubated with each piper-
azine designer drug at EC20, EC40 and EC60 for 24 h. At the end of
the incubation period, the medium was replaced by fresh medium
containing 2 lM TMRE, and incubated at 37 C, for 30 min, in the
dark. As TMRE is a non water-soluble powder, a 2 mM stock solu-
tion was initially prepared in DMSO and stored at 20 C, pro-
tected from light. Afterward, the medium was gently aspirated
and replaced by 0.2% BSA in HBSS. Fluorescence was measured
on a ﬂuorescence microplate reader (BioTek Instruments,
Vermont, USA) set to 544 nm excitation and 590 nm emission.
The data obtained were calculated as the percentage of control
conditions from four independent experiments with each concen-
tration tested in six replicates within each experiment.
2.11. Caspase-3 activity assay
Primary rat hepatocytes were seeded at a density of 1  106
viable cells/well onto 6-well plates. After 24 h incubation, at
37 C, with each piperazine designer drug at EC20, EC40 and EC60,
the cells were detached and collected to a tube (2 wells per tube),
centrifuged (210g, 5 min, 4 C), and the supernatant was discarded.
One hundred and ﬁfty microliters of lysis buffer (50 mM HEPES,
0.1 mM EDTA, 0.1% CHAPS, supplemented with 1 mM DTT, pH
7.4) were added to the pellets, vortex-mixed and incubated on
ice for 5 min before centrifugation (16,000g, 10 min, 4 C). In a
96-well plate, 50 lL of the supernatant, which contains the cyto-
plasmic fraction, was mixed with 200 lL of assay buffer (100 mM
NaCl, 50 mM HEPES, 1 mM EDTA, 0.1% CHAPS, 10% glycerol, sup-
plemented with 10 mM DTT, pH 7.4). The reaction was started by
adding 5 lL of caspase-3 peptide substrate Ac-DEVD-pNA (ﬁnal
concentration 80 lM), with subsequent incubation at 37 C for
24 h. Caspase-3 releases the p-nitroaniline moiety of the substrate,
which presents high absorbance at 405 nm. All steps were per-
formed on ice and the caspase-3 activity was determined at
405 nm in a multi-well plate reader (BioTech Instruments,
Vermont, US) as previously described (Arbo et al., 2014).
Table 1
EC50 values of the piperazine designer drugs in the MTT assay, after 24 h-incubations
at 37 C.
Designer drug EC50 (mM)
HepG2 HepaRG Rat hepatocytes
BZP 6.75b,c,d,$ 6.58b,c,d,$ 2.15b,d,*,#
TFMPP 0.31a,c,d,#,$ 0.46a,c,d,*,$ 0.13a,c,d,*,#
MeOPP 3.31a,b,#,$ 4.33a,b,d,*,$ 2.08b,d,*,#
MDBP 3.62a,b 3.65a,b,c 3.74a,b,c
The cytotoxicity curves were ﬁtted using the dosimetric logit model, p values < 0.05
were considered statistically signiﬁcant.
a Compares to BZP.
b Compares with TFMPP.
c Compares with MeOPP.
d Compares with MDBP.
* Compares to HepG2.
# Compares to HepaRG.
$ Compares to rat hepatocytes.
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DTT were prepared in DMSO. The absorbance of blanks, used as
non-enzymatic control, was subtracted from each value of absor-
bance and the data normalized with the amount of protein of each
sample. The protein content in the cytoplasmic fraction was quan-
tiﬁed using the Bio-Rad DC protein assay kit as described by the
manufacturer, and bovine albumin solutions were used as stan-
dards. Results from four independent experiments were expressed
as fold increase over controls. Campthotecin (12 lM) was used as
positive control.
2.12. Statistical analysis
The normalized MTT data were ﬁtted to the dosimetric logit
model (Dias da Silva et al., 2014a), that was chosen based on a sta-
tistical goodness-of-ﬁt principle (Scholze et al. 2001). Comparisons
between concentration–response curves were performed using the
extra sum-of-squares F test. Results of ROS/RNS GSH, GSSG, Dwm,
ATP, and caspase-3 assays are presented as mean ± standard error
of the mean (SEM) from 4 independent experiments. Normality of
the data distribution was assessed by the Kolmogorov–Smirnov
normality test. Statistical comparisons between groups were per-
formed by one-way analysis of variance (ANOVA) followed by
Dunn’s multiple comparison test. Solvent and negative control val-
ues obtained in the MTT assay were compared by the Student’s
unpaired t-test. In all cases, signiﬁcance was accepted at p val-
ues < 0.05. All statistical calculations were performed using
GraphPad Prism software, version 5.01 (GraphPad Software, San
Diego, CA, USA).3. Results
3.1. Piperazine designer drugs elicited hepatotoxicity in vitro
Fig. 1 presents the concentration–response curves of each
piperazine designer drug in the three in vitro models evaluated in
this work, human derived HepG2 and HepaRG cells and primary
rat hepatocytes. Exposure to piperazine drugs resulted in concen-
tration-dependent cytotoxicity. A summary of the calculated EC50
values (representing the half-maximum-effect concentrations
from the curves) is presented in Table 1. Signiﬁcant differencesFig. 1. Concentration–response (cell death) curves of piperazine designer drugs in Hep
Viability was evaluated through the MTT reduction assay. Data are presented as percenta
experiments were performed (six replicates tested for each concentration within each ewere observed for the EC50 values of the curves (p < 0.05, F test).
Based on these data, it was evident that, under our experimental
conditions, TFMPP was the most cytotoxic piperazine designer
drug in the three in vitro models evaluated. HepaRG cells proved
to be the most resistant model to the toxicity elicited by all piper-
azine drugs (p values < 0.0001, when curves were compared for the
EC50 values), except for MDBP, when cells were exposed to concen-
trations higher than the EC50. In the case of BZP, there was no sig-
niﬁcant difference between the HepG2 and HepaRG cytotoxicity
curves. Primary rat hepatocytes showed to be the most sensitive
cells to study the hepatotoxicity of the piperazine designer drugs
(p values < 0.0001), when curves were compared for the EC50 val-
ues. For MDBP, there was observed no signiﬁcant differences
among the three in vitromodels. Therefore, all further toxicological
evaluations were carried out in this model.3.2. Metabolism does not contribute to the cytotoxicity of piperazine
designer drugs in rat primary hepatocytes
The metabolism of piperazine designer drugs is dependent of
CYP450 activity. Fig. 2 presents the concentration–response curves
obtained after the co-incubation of each piperazine designer drugG2 and HepaRG cells and primary rat hepatocytes after 24 h incubations at 37 C.
ge of cell death relative to the respective negative controls. At least four independent
xperiment). Curves were ﬁtted using the dosimetric logit model.
Fig. 2. Concentration–response (cell death) curves of primary rat hepatocytes after 24 h of co-incubation of each piperazine designer drug with 500 lM metyrapone or
100 lM quinidine at 37 C. Viability was evaluated through the MTT reduction assay. Data are presented as percentage of cell death relative to the respective negative
controls. Three independent experiments were performed (six replicates tested for each concentration within each experiment). Curves were ﬁtted using the dosimetric logit
model.
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100 lM quinidine (inhibitor of CYP2D6) in primary rat hepato-
cytes. There was no signiﬁcant difference between negative and
solvent controls and the CYP450 inhibitors alone at the concentra-
tions tested. The attained EC50 values are displayed in Table 2. With
the exception of MDBP incubations with metyrapone, where no
differences were observed, all other curves representing the co-in-
cubation of the piperazine designer drugs with the CYP inhibitors
showed a deviation to the left in relation to the curves obtained
with the drugs alone. This indicates that the CYP450-mediated
metabolism has a detoxifying effect, and it is most likely that the
parent compounds are more toxic than their metabolites.
3.3. Piperazine designer drugs induce oxidative stress in rat primary
hepatocytes
The formation of ROS and/or RNS and the resulting oxidative
and/or nitrosative stress is a common toxicological pathway of
hepatotoxicity for drugs of abuse (e.g. amphetamines), and phar-
maceuticals (e.g. azathioprine and paracetamol) (Pandit et al.,
2012). As depicted in Fig. 3, piperazine designer drugs induced
the production of reactive species after 24 h incubations in primary
rat hepatocytes, as evaluated by the DCFH-DA assay. This effect
was signiﬁcant (p < 0.05, ANOVA/Dunn’s) and concentration-de-
pendent for all the tested drugs. Interestingly, among the same
cytotoxicity level, MeOPP signiﬁcantly (p < 0.0001, ANOVA/Table 2
EC50 values of the piperazine designer drugs co-incubated with CYP450 inhibitors
metyrapone (500 lM) and quinidine (100 lM) in the MTT assay, after 24 h at 37 C.
Designer drug EC50 (mM)
No inhibitor Metyrapone (500 lM) Quinidine (100 lM)
BZP 3.06 2.35* 1.93*
TFMPP 0.30 0.24* 0.16*
MeOPP 1.71 1.68 1.10*
MDBP 1.70 1.58 1.13*
The cytotoxicity curves were ﬁtted using the dosimetric logit model.
* Statistically signiﬁcant comparing to the piperazine drugs alone (p < 0.05).Dunn’s) induced more reactive species formation than the other
drugs. At equipotent cytotoxic concentrations, no signiﬁcant differ-
ences were observed among BZP, TFMPP and MDBP.
GSH is considered to be the ﬁrst line of defense against oxida-
tive damage and free radicals generation and were investigated
with the DTNB–GSSG reductase recycling assay. As shown in
Fig. 4, a signiﬁcant (p < 0.001, ANOVA/Dunn’s) GSH depletion was
noted at all concentrations of BZP and MDBP. A concentration-de-
pendent effect was observed for MeOPP, where a signiﬁcant
(p < 0.001, ANOVA/Dunn’s) depletion was observed at EC40 and
EC60 compared to control. For BZP it was also possible to observe
a signiﬁcant (p < 0.01, ANOVA/Dunn’s) increase in GSSG levels at
the tested EC20 and EC40. Interestingly, these results agree with
the generation of reactive species, since the highest GSH depletion
was observed at EC60 MeOPP, which also induced the highest for-
mation of reactive species. Comparing all piperazine designer
drugs at equipotent cytotoxic concentrations, MDBP and BZP had
a greater effect in GSH depletion. BZP signiﬁcantly increased
(p < 0.01, ANOVA/Dunn’s) the GSSG intracellular levels to a greater
extent than that observed for any of the other drugs. TFMPP did not
induce any alteration in GSH homeostasis.
3.4. Piperazine designer drugs induce mitochondrial impairment and
disturb energetic status in rat primary hepatocytes
Mitochondria participates in several vital functions to the cell,
which includes energy production, through ATP generation, and
Ca2+ buffering. The mitochondrial membrane potential (Dwm)
was evaluated in order to investigate whether the piperazine drugs
could disturb the mitochondrial function. A signiﬁcant loss ofDwm
impairs oxidative phosphorylation, depleting cells of energy, and
inducing cell death. In Fig. 5, a signiﬁcant (p < 0.01, ANOVA/
Dunn’s) loss in Dwm can be observed after 24 h incubations of pri-
mary rat hepatocytes with all drugs at all concentrations, except
for EC20 TFMPP, in relation to control. Comparing all drugs at the
same toxicity levels, the highest mitochondrial depolarization
was observed with MDBP, at EC20 and EC40. This loss of Dwm
was signiﬁcantly higher (p < 0.01, ANOVA/Dunn’s) than for all the
other drugs at equipotent concentrations. MeOPP and BZP
Fig. 3. Reactive species (ROS/RNS) production, measured through the DCFH-DA assay, in rat primary hepatocytes after 24 h-incubations with each piperazine designer drug
at 37 C. Results are expressed as percentage control ± SEM (n = 4 independent experiments run in triplicates). Statistical comparisons were made using one-way ANOVA/
Dunn’s post hoc test (p < 0.05). ⁄ compares to control; $ compares to BZP, # compares to TFMPP, and & compares to MeOPP at the same cytotoxicity levels (EC20, EC40 or EC60).
Fig. 4. Intracellular contents of GSH and GSSG in rat primary hepatocytes after 24 h of incubation with BZP (A), TFMPP (B), MeOPP (C) and MDBP (D). Results are expressed as
mean ± SEM (n = 4 independent experiments). Statistical comparisons were made using one-way ANOVA/Dunn’s post hoc test (p < 0.05). ⁄ compares to control GSH, x
compares to control GSSG. Comparing the same cytotoxicity levels (EC20, EC40, or EC60): $ compares to BZP GSH,  compares to BZP GSSG; # compares to TFMPP GSH, §
compares to TFMPP GSSG; & compares to MeOPP GSH,  compares to MeOPP GSSG.
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other hand, TFMPP presented the lowest effect on Dwm.
ATP is the key intermediate for energy exchange, it is related
with cellular energetics, metabolic regulation, and signaling. All
cells require ATP to remain alive and carry out their speciﬁc func-
tions and, because ATP is transiently depressed by many forms ofcellular stress, its levels reﬂect the functional integrity of viable
cells. Fig. 6 shows that the intracellular ATP levels measured in pri-
mary rat hepatocytes exposed to the tested piperazine designer
drugs for 24 h at 37 C were signiﬁcantly depleted for all concen-
trations, with the exception of EC20 BZP, and EC20 and EC40
TFMPP. Interestingly, the drug presenting the highest ATP
Fig. 5. Mitochondrial membrane potential (Dwm) measured as TMRE incorporation in mitochondria of rat primary hepatocytes after 24 h incubations with the tested
piperazine designer drugs at 37 C. Results are expressed as percentage control ± SEM (n = 4 independent experiments run in triplicates). Statistical comparisons were made
using one-way ANOVA/Dunn’s post hoc test. ⁄ compares to control; $ compares to BZP, and # compares to TFMPP at the same cytotoxicity levels (EC20, EC40 or EC60).
Fig. 6. Intracellular ATP levels in primary rat hepatocytes after 24 h of incubation with piperazine designer drugs at 37 C. Results are expressed as mean ± SEM (n = 4
independent experiments). Statistical comparisons were made using one-way ANOVA/Dunn’s post hoc test. ⁄ compares to control; $ compares to BZP, and # compares to
TFMPP at the same cytotoxicity levels (EC20, EC40 or EC60).
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sented the highest Dwm loss. As observed for the Dwm loss
induced by MeOPP and BZP, a similar effect in the same cytotoxic-
ity level for these two drugs was observed for ATP depletion.
Among all drugs, TFMPP exerted the lowest effect on ATP levels.
3.5. Piperazine designer drugs induce caspase activation in primary rat
hepatocytes
Caspase activation is one the main events leading to apoptosis.
As can be seen in Fig. 7, a signiﬁcant (p < 0.01, ANOVA/Dunn’s)
increase in caspase-3 activity occurred at almost all concentrations
of the tested piperazine designer drugs after 24 h incubations inprimary rat hepatocytes. Among all tested drugs, the highest cas-
pase-3 activation was observed with MDBP (p < 0.01, ANOVA/
Dunn’s). A concentration–response effect was noted for MeOPP
and BZP. At equipotent concentrations, TFMPP presented the low-
est caspase-3 activation.
4. Discussion
The effects experienced by users after piperazine designer drugs
intake resemble those of the amphetamines (Lin et al., 2011). The
liver is one of the main targets of toxicity for amphetamine-like
drugs (Carvalho et al., 2010) and cathinone derivatives (Araújo
et al., 2014). The available information on the toxic effects of
Fig. 7. Caspase-3 activity fold increase in primary rat hepatocytes after 24 h incubations with piperazine designer drugs at 37 C. Results are expressed as mean ± SEM (n = 4
independent experiments). Statistical comparisons were made using one-way ANOVA/Dunn’s post hoc test. ⁄ compares to control; $ compares to BZP, and # compares to
TFMPP at the same cytotoxicity levels (EC20, EC40 or EC60).
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recent studies indicate that these drugs present cardiotoxic effects
in vitro (Arbo et al., 2014).
For the ﬁrst time, we demonstrate that piperazine designer
drugs produced hepatotoxicity to three different in vitro models
(HepG2 and HepaRG cells, and primary rat hepatocytes) being
TFMPP the most potent designer drug in all of them. We selected
the human-derived hepatoblastoma cell line HepG2 not only
because these cells have been extensively used as a test system
for the prediction of toxicity, carcinogenicity and cell mutagenicity
in humans (Donato et al., 2008; Liu and Zeng, 2009) but also
because they have been previously used for the characterization
of the cytotoxic effects of other designer drugs of abuse, including
amphetamines (Dias da Silva et al., 2013a–c, 2014a,b). However,
there is a major limitation of this cellular model concerning drug
metabolism since, in these hepatic cells, drug-metabolizing
enzymes, namely CYP isoforms, are expressed at very low levels
when compared with primary hepatocytes or with the in vivo situ-
ation (Guo et al., 2011; Lin et al., 2012). To overcome this limita-
tion, the cytotoxicity studies were also conducted in HepaRG
cells. This is another human cell line derived from a hepatocellular
carcinoma which exhibits extensive differentiation after 2 weeks
in culture. After acquiring a differentiated hepatocyte-like mor-
phology, they retain a unique set of drug-metabolizing enzymes
at levels comparable to those observed with primary human hep-
atocytes in culture. Comparing to HepG2 cells, HepaRG present a
higher level of CYP1A1, CYP2B6, CYP2C9, CYP2E1 and CYP3A4
mRNA but lower CYP2D6 mRNA (Aninat et al., 2006; Rodrigues
et al., 2013). The main metabolic pathways described for the piper-
azine designer drugs in animals and in humans comprise reactions
catalyzed by CYP2D6 which include the hydroxylation of BZP
(Staack and Maurer, 2005), TFMPP (Staack et al., 2003), and the
demethylenation of MeOPP (Staack et al., 2004) and MDBP
(Staack and Maurer, 2004). Since CYP2D6 is present at low levels
in both immortalized cellular models, we also included rat primary
hepatocytes in this study. Primary hepatocytes have some draw-
backs such as, unpredictable viability, limited growth activity
and lifespan, early phenotypic alterations after seeding, besides
huge variations in functional activities, especially CYP levels.Nevertheless, primary hepatocytes are the most suitable model
for investigating the induction of CYPs by chemical inducers and
the metabolic proﬁles of new drugs (Aninat et al., 2006).
In all models, TFMPP was the most cytotoxic drug, which agrees
with previous ﬁndings in cardiomyoblast H9c2 cells (Arbo et al.,
2014). The main differences among the in vitromodels used in this
work concerns their metabolic capacity. Since the susceptibility of
the primary hepatocytes to the cytotoxicity of the piperazine drugs
was remarkably higher than those of the HepG2 and HepaRG cells,
except for MDBP, it could be anticipated that their higher meta-
bolic competence could explain these differences. Surprisingly,
when we co-incubated the piperazine designer drugs with the
CYP inhibitor metyrapone and the CYP2D6 inhibitor quinidine, an
increase in the potency of the drug was observed. The deviation
of the curves to the left, which was even more evident when cells
were co-incubated with quinidine, suggests that metabolism plays
a detoxifying role for the piperazine designer drugs.
The discrepancies in EC50 values of immortalized cells and pri-
mary hepatocytes are quite expected. The immortalization process
adds new characteristics to the cells, namely the continuous
growth and an almost unlimited life-span, which can induce differ-
ent physiological responses compared to the primary cells. Besides
the difference in CYP expression among the in vitro models, some
transporters, such as the organic cation transporters (OCTs), are
also under expressed in hepatic immortalized cells. The OCTs are
present in the basolateral membrane of hepatocytes and could play
a role in the uptake of drugs by the hepatocyte (Tu et al., 2013).
Therefore, an advantage of the use of primary cells is that the cell
phenotype comprises a much more reliable situation (Astashkina
et al., 2012). Since the immortalized cells are from human origin
and the primary hepatocytes from rats, it is also necessary to con-
sider possible interspecies differences that could explain different
rates of metabolism and toxicological susceptibilities.
Piperazine designer drugs induce the formation of reactive spe-
cies in primary rat hepatocytes, a situation also observed with
amphetamine derivatives in primary rat hepatocytes (Pontes
et al., 2008) and HepG2 cells (Dias da Silva et al., 2014a).
Interestingly, MeOPP presented a pro-oxidant effect higher than
the other drugs, and this could be due to the MeOPP metabolism.
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followed by N-acetylation, lead to the formation of N-acetyl-4-hy-
droxyaniline that corresponds to the analgesic drug acetamino-
phen (paracetamol) (Staack et al., 2004; Staack and Maurer,
2005), that can be further metabolized into N-acetyl-p-benzo-
quinone imine, a highly oxidative and GSH depleting chemical.
On the other hand, this ﬁnding is not corroborated by our previous
work with these piperazine designer drugs in rat cardiomyoblasts
H9c2, where no signiﬁcant increase of reactive species occurred
(Arbo et al., 2014). However, comparing the two in vitro models,
rat hepatocytes have a much more efﬁcient metabolic capacity
than the rat derived cardiomyoblast cells, which could lead to an
exacerbated production of free radicals.
Events reﬂecting GSH depletion have been considered as poten-
tial biomarkers of drug-induced hepatotoxicity (Yuan and
Kaplowitz, 2009). Piperazine designer drugs elicited intracellular
GSH depletion, which is related to the increased intracellular pro-
duction of reactive species. The expected increases in intracellular
GSSG levels were not observed for all drugs, possibly due to GSSG
efﬂux. The formed GSSG is extruded for the extracellular medium
as a protective response of the cells against oxidative stress.
With the exception of BZP, the decreases in intracellular GSH con-
tents were not accompanied by an increase in GSSG levels. This is
not surprising, and has been previously reported for amphetamine
derivatives in hepatocytes (Hiramatsu et al., 1990; Carvalho et al.,
1996, 2004; Dias da Silva et al., 2014a). Regarding GSH homeosta-
sis, an important role contributing to GSH depletion can be played
by the metabolism of hepatocytes through conjugation reactions
with GSH (Carvalho et al., 2001). In fact, it has been shown that
the aromatic hydroxylation of amphetamine into p-hydroxyam-
phetamine leads to the formation of the glutathione-S-yl-p-hy-
droxyamphetamine conjugate through a reaction that is
catalyzed by CYP2D6 and likely involves the formation of an arene
epoxide intermediate (Carvalho et al., 1996). An alternative mech-
anism involving the formation of catechol metabolites that are oxi-
dized into quinone intermediates following demethylenation of
MDMA (Hiramatsu et al., 1990) and methylenedioxyamphetamine
(MDA) (Carvalho et al., 2004) has also been shown to produce the
corresponding glutathione-S-yl-N-methyl-a-methyldopamine and
glutathione-S-yl-a-methyldopamine conjugates. There is a striking
similarity between these metabolic pathways and those that were
already described for the piperazine designer drugs in animals and
in humans (Staack and Maurer, 2005). Interestingly, MDBP, which
produces a catechol intermediate as a metabolite, induced a signif-
icant GSH depletion at all tested concentrations.
There are growing reports that mitochondria is a primary or
secondary drug target and that its impairment is one of the major
contributors to drug-induced liver injury (Scatena et al., 2007). Our
data point to a depolarization of mitochondria and ATP depletion
after 24 h incubations of primary rat hepatocytes with piperazine
designer drugs. The Dwm is crucial for maintaining the physiolog-
ical function of the mitochondrial respiratory chain, a process
responsible for ATP generation. A signiﬁcant loss of Dwm impairs
oxidative phosphorylation, depleting cells of energy and inducing
cell death. Translocation of protons from the matrix to the inter-
membrane space to establish Dwm is coupled to the mitochondrial
electron transport chain (Yuan and Acosta, 1996). Inhibition of
complex I and/or II of the electron transport chain leads to an
increase of reactive oxygen species and a decrease in ATP produc-
tion with subsequent accumulation of dysfunctional proteins,
which impairs mitochondrial function (Usta et al., 2009).
Depletion of ATP is a typical feature of hypoxic and toxic injury,
and leads to inhibition of two hepatic anabolic processes, namely
gluconeogenesis and plasma protein synthesis, which have in com-
mon a substantial requirement for ATP (Ponsoda et al., 1995).
Interestingly, the impairment of mitochondrial function, leadingto ATP depletion, was also observed in our previous studies using
H9c2 rat cardiomyoblasts (Arbo et al., 2014), which may indicate
that this is an important event in the cytotoxicity triggered by
the piperazine designers drugs. Among all the tested drugs, the
highest mitochondrial depolarization, and consequently, ATP
depletion, was observed with MDBP.
Mitochondria also play a major role in apoptosis, by mediating
and propagating death signals originated from the inside (intrinsic
apoptotic pathway) or outside (extrinsic apoptotic pathway) of the
cell, and loss ofDwm is an early apoptotic event. The observed acti-
vation of downstream caspase-3 is an indicative of the preference
for apoptosis, as the main cell death mode and agrees well to what
has already been described for amphetamines tested under nor-
mothermic conditions (Capela et al., 2013; Dias da Silva et al.,
2013c). As with the effects observed in Dwm and ATP depletion,
MDBP presented the highest downstream caspase-3 activation.
Interestingly, after 24 h incubations of rat cardiomyoblasts with
these piperazine designer drugs, signs of apoptosis were also
found, but no activation of caspase-3 was observed (Arbo et al.,
2014), which means that cell-speciﬁc mechanisms may be
involved in the cytotoxic effects and cell death mode induced by
these drugs.
In conclusion, we have demonstrated for the ﬁrst time the
in vitro hepatotoxic effects of piperazine designer drugs in three
in vitro models, the HepG2, HepaRG cells, and primary rat hepato-
cytes. The rat primary hepatocytes were the most sensitive model
in detecting deleterious effects and TFMPP was the most potent
drug. In rat hepatocytes, piperazine designer drugs induced oxida-
tive stress, loss of Dwm, ATP depletion and caspase-3 activation.
Comparing all drugs at equipotent cytotoxic concentrations, differ-
ences in mechanisms of toxicity were evident, especially for
TFMPP, indicating that additional toxicity endpoints should be
evaluated for a better comprehension of the mechanisms involved
in the cytotoxicity of the piperazine designer drugs.
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